Centivax signs licensing agreement with Thermo Fisher for its anti-COVID-19 antibodies

Centivax Inc, the therapeutics spinout of Contract Research Organization Distributed Bio Inc, announced today a licensing agreement with Thermo Fisher Scientific. Thermo Fisher has developed and evaluated several variants of Centivax’s highly specific and effective therapeutic antibody candidates against COVID-19 for use in research, including flow cytometry, histopathology, in vitro and in vivo neutralization, Luminex…

Nature Communications publishes Bluestar Genomics’ technology for cancer detection study

Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, announced today the publication of study results in the peer-reviewed journal Nature Communications. The study demonstrates the power of the company’s platform to detect pancreatic cancer in its early stages, addressing the unmet need of more than 60,000 patients…

NYSCF announces 2020 Class of NYSCF – Robertson Investigators

The New York Stem Cell Foundation (NYSCF) today announced the 2020 class of NYSCF – Robertson Investigators, welcoming six outstanding stem cell researchers and neuroscientists into the NYSCF Investigator Program. The NYSCF Investigator Program fosters and encourages promising early career scientists whose cutting-edge research holds the potential to accelerate treatments and cures through the NYSCF…